Clobetasol propionate (Dermovate) gives new opportunities in the treatment ofdermatoses



Cite item

Full Text

Abstract

The author provides a review of literature covering studies of the efficacy and safety of a very powerful topical corticosteroid -
clobetasol propionate (Dermovate). It surpasses most topical glucocorticoids by its action and efficacy for steroid-responsive
dermatoses. The drug has several forms convenient for use for different localizations. It is a drug of choice for medium and severe
psoriasis. It is efficient in treatment of a wide range of torpid dermatoses as well as dermatoses resistant to other topical drugs.
This drug is safe under the condition of its reasonable administration. The development of serious complications is possible only
in case of long-term administration of extremely high doses.

About the authors

A N Khlebnikova

Email: alb9696@yandex.ru

References

  1. Sulzberger M.B., Witten V.H. The effect of topicallyapplied compound F in selected dermatoses. J Invest Dermatol 1952; 19: 101-102.
  2. Yohn J.J Weston W.L. Topical glucocorticosteroids. Curr Probl Dermatol 1990; 2: 31-63.
  3. McKenzie A.W., Stoughton R.B. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86: 606-10.
  4. Yang S., Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004; 2(1): 1-12.
  5. Cornell R.C., Stoughton R.B. Correlation of the skin blanching assay and clinical activity in. psoriasis. Arch Dermatol 1985; 121: 63-67.
  6. Белоусова Т.А., Кочергин Н.Г., Кривда А.Ю. Кортикостероидные препараты для наружного применения. Рос журн кож вен бол 1998; 3: 78-79.
  7. Robertson D.B., Maibach H.I. Topical corticosteroids. Int J Dermatol 1982; 21: 59-67.
  8. Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
  9. Gordon M.L. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses. Clin Ther 1998; 20(1): 26-39.
  10. Pearce D.J., Stealey K.H., Balkrishnan R., Fleischer A.B.Jr., FeldmanS.R. Psoriasis. treatment in the United States at the end of the20th century. Int J Dermatol 2006; 45: 370-374.
  11. Barnes P.J Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998; 94: 557-572.
  12. Carruthers J.A., August P.J., Staughton R.C. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975; 25: 203-204.
  13. Olsen E.A., Cornell R.C. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15: 246-255.
  14. Hehir M., duVivier A., Eilon L. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983; 8: 143-151.
  15. Jacobson C., Cornell R.C., Savin R.C. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis 1986; 37: 213-220.
  16. Sommer A., Lucassen G.W., Houben A.J., Neumann M.H. Vasoconstrictive effect of topical applied corticosteroids measured by laser Doppler imaging and reflectance spectroscopy. Microvasc Res 2003; 65: 152-159.
  17. Emtestam L., Kuzmina N., Talme T. Evaluation of the effects of topical clobetasol propionate by visual score, electrical impedance and laser Doppler flowmetry. Skin Res Technol 2007; 13: 73-78.
  18. Falkenstein E., Tillmann H.C., Christ M.,Feuring M., Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomiceffects. Pharmacol. Rev 2000; 52:513-556.
  19. Serres M., Viac J., Schmitt D. Glucocorticoid receptor localization in human epidermal cells. Arch Dermatol Res 1996; 288: 140-146.
  20. Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stuetz A.,Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684.
  21. Barnes P.J Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998; 94: 557-572.
  22. Croxtall J.D., Choudhury Q., Flower R.J Glucocorticoids act within minutes to inhibit. recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000; 130: 289-298.
  23. Naumann L., Feist E., Straub R.H., Burmester G.R., Buttgereit F. Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral. blood mononuclear cells. Biochem. Pharmacol. 2006; 71: 530-539.
  24. Schmid D., Burmester G.R., Tripmacher R., Kuhnke A., ButtgereitF. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000; 20: 289-302.
  25. Portner M., Mollmann H., Rohdewald P. Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid- 21-esters. Pharm Res 1988; 5: 623-627.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Khlebnikova A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies